S&P 500   3,150.01 (+1.05%)
DOW   28,024.58 (+1.25%)
QQQ   204.98 (+1.26%)
AAPL   270.79 (+1.96%)
FB   200.84 (+0.74%)
MSFT   151.28 (+0.90%)
GOOGL   1,338.91 (+1.51%)
AMZN   1,751.76 (-0.51%)
NVDA   212.01 (+1.24%)
MU   47.87 (+2.68%)
BABA   201.37 (+0.69%)
GE   11.01 (+2.04%)
TSLA   337.22 (+1.26%)
T   38.31 (+0.31%)
AMD   39.65 (-0.10%)
ACB   2.42 (-0.82%)
F   9.01 (+0.90%)
PRI   136.13 (+1.36%)
NFLX   305.73 (+0.46%)
BAC   33.78 (+2.09%)
GILD   67.24 (+0.72%)
DIS   148.05 (+0.41%)
S&P 500   3,150.01 (+1.05%)
DOW   28,024.58 (+1.25%)
QQQ   204.98 (+1.26%)
AAPL   270.79 (+1.96%)
FB   200.84 (+0.74%)
MSFT   151.28 (+0.90%)
GOOGL   1,338.91 (+1.51%)
AMZN   1,751.76 (-0.51%)
NVDA   212.01 (+1.24%)
MU   47.87 (+2.68%)
BABA   201.37 (+0.69%)
GE   11.01 (+2.04%)
TSLA   337.22 (+1.26%)
T   38.31 (+0.31%)
AMD   39.65 (-0.10%)
ACB   2.42 (-0.82%)
F   9.01 (+0.90%)
PRI   136.13 (+1.36%)
NFLX   305.73 (+0.46%)
BAC   33.78 (+2.09%)
GILD   67.24 (+0.72%)
DIS   148.05 (+0.41%)
S&P 500   3,150.01 (+1.05%)
DOW   28,024.58 (+1.25%)
QQQ   204.98 (+1.26%)
AAPL   270.79 (+1.96%)
FB   200.84 (+0.74%)
MSFT   151.28 (+0.90%)
GOOGL   1,338.91 (+1.51%)
AMZN   1,751.76 (-0.51%)
NVDA   212.01 (+1.24%)
MU   47.87 (+2.68%)
BABA   201.37 (+0.69%)
GE   11.01 (+2.04%)
TSLA   337.22 (+1.26%)
T   38.31 (+0.31%)
AMD   39.65 (-0.10%)
ACB   2.42 (-0.82%)
F   9.01 (+0.90%)
PRI   136.13 (+1.36%)
NFLX   305.73 (+0.46%)
BAC   33.78 (+2.09%)
GILD   67.24 (+0.72%)
DIS   148.05 (+0.41%)
S&P 500   3,150.01 (+1.05%)
DOW   28,024.58 (+1.25%)
QQQ   204.98 (+1.26%)
AAPL   270.79 (+1.96%)
FB   200.84 (+0.74%)
MSFT   151.28 (+0.90%)
GOOGL   1,338.91 (+1.51%)
AMZN   1,751.76 (-0.51%)
NVDA   212.01 (+1.24%)
MU   47.87 (+2.68%)
BABA   201.37 (+0.69%)
GE   11.01 (+2.04%)
TSLA   337.22 (+1.26%)
T   38.31 (+0.31%)
AMD   39.65 (-0.10%)
ACB   2.42 (-0.82%)
F   9.01 (+0.90%)
PRI   136.13 (+1.36%)
NFLX   305.73 (+0.46%)
BAC   33.78 (+2.09%)
GILD   67.24 (+0.72%)
DIS   148.05 (+0.41%)
Log in

NASDAQ:PHAT - Phathom Pharmaceuticals Stock Price, Forecast & News

$26.03
-0.72 (-2.69 %)
(As of 12/6/2019 12:47 PM ET)
Today's Range
$25.41
Now: $26.03
$27.49
50-Day Range N/A
52-Week Range
$20.26
Now: $26.03
$28.51
Volume1,975 shs
Average Volume94,004 shs
Market Capitalization$638.44 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium competitive acid blocker (P-CAB) in late clinical-stage development for the treatment of gastric acid-related diseases. It also plans to initiate a Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease and the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is based in Buffalo Grove, Illinois.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PHAT
CUSIPN/A
CIKN/A
Phone650-325-5156

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees12
Market Cap$638.44 million
Next Earnings Date2/24/2020 (Estimated)
OptionableNot Optionable

Receive PHAT News and Ratings via Email

Sign-up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter.


Phathom Pharmaceuticals (NASDAQ:PHAT) Frequently Asked Questions

What is Phathom Pharmaceuticals' stock symbol?

Phathom Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAT."

When is Phathom Pharmaceuticals' next earnings date?

Phathom Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Phathom Pharmaceuticals.

What price target have analysts set for PHAT?

4 analysts have issued 12-month price objectives for Phathom Pharmaceuticals' stock. Their forecasts range from $32.00 to $40.00. On average, they anticipate Phathom Pharmaceuticals' stock price to reach $34.67 in the next twelve months. This suggests a possible upside of 33.2% from the stock's current price. View Analyst Price Targets for Phathom Pharmaceuticals.

What is the consensus analysts' recommendation for Phathom Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phathom Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Phathom Pharmaceuticals.

Has Phathom Pharmaceuticals been receiving favorable news coverage?

News headlines about PHAT stock have been trending somewhat positive recently, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Phathom Pharmaceuticals earned a coverage optimism score of 1.7 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the stock's share price in the next several days. View News Stories for Phathom Pharmaceuticals.

Who are some of Phathom Pharmaceuticals' key competitors?

What other stocks do shareholders of Phathom Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Phathom Pharmaceuticals investors own include Chipotle Mexican Grill (CMG), Biogen (BIIB), Constellation Pharmaceuticals (CNST), Lam Research (LRCX), Advanced Drainage Systems (WMS), Adobe (ADBE), Amkor Technology (AMKR), Anika Therapeutics (ANIK), Baidu (BIDU) and Cabaletta Bio (CABA).

Who are Phathom Pharmaceuticals' key executives?

Phathom Pharmaceuticals' management team includes the folowing people:
  • Mr. David Socks, Co-Founder, Pres, CEO, Treasurer, Sec. & Director (Age 45)
  • Dr. Tadataka Yamada B.A., M.D., Ph.D., KBE, Co-Founder & Chairman (Age 73)
  • Dr. Azmi Nabulsi, Co-Founder & COO (Age 60)
  • Mr. Aditya Kohli Ph.D., Co-Founder & Chief Bus. Officer (Age 31)
  • Dr. Roger Ulrich, Co-Founder & Chief Scientific Officer

When did Phathom Pharmaceuticals IPO?

(PHAT) raised $150 million in an IPO on Friday, October 25th 2019. The company issued 7,900,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, Jefferies and Evercore ISI acted as the underwriters for the IPO and Needham & Company was co-manager.

When did the company's quiet period expire?

Phathom Pharmaceuticals' quiet period expired on Wednesday, December 4th. Phathom Pharmaceuticals had issued 9,563,157 shares in its IPO on October 25th. The total size of the offering was $181,699,983 based on an initial share price of $19.00. During the company's quiet period, underwriters and any insiders involved in the IPO were prevented from issuing any research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Phathom Pharmaceuticals?

Shares of PHAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Phathom Pharmaceuticals' stock price today?

One share of PHAT stock can currently be purchased for approximately $26.03.

How big of a company is Phathom Pharmaceuticals?

Phathom Pharmaceuticals has a market capitalization of $638.44 million. Phathom Pharmaceuticals employs 12 workers across the globe.View Additional Information About Phathom Pharmaceuticals.

What is Phathom Pharmaceuticals' official website?

The official website for Phathom Pharmaceuticals is http://www.phathompharma.com/.

How can I contact Phathom Pharmaceuticals?

Phathom Pharmaceuticals' mailing address is 2150 EAST LAKE COOK ROAD SUITE 800, BUFFALO GROVE IL, 60089. The company can be reached via phone at 650-325-5156 or via email at [email protected]


MarketBeat Community Rating for Phathom Pharmaceuticals (NASDAQ PHAT)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  13 (Vote Outperform)
Underperform Votes:  10 (Vote Underperform)
Total Votes:  23
MarketBeat's community ratings are surveys of what our community members think about Phathom Pharmaceuticals and other stocks. Vote "Outperform" if you believe PHAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PHAT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/6/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel